Talk Description
507C - Research Paper
Abstract
Case Description:
59yo man on HD 3x week with Class 2 obesity (BMI 35.4kg/m2) attended the metabolic rehabilitation clinic and was commenced on OzempicR as part of his weight loss program with the plan to be listed for a renal transplant. A fortnight after commencing OzempicR he began complaining of increasing abdominal pain. Upon investigation he informed the staff he had not moved his bowels in 15days.
Discussion:
Despite the GLP-1Ras being hailed as the golden ticket for people struggling with obesity they are not without their risks and cannot be used in isolation. The underlying cause of obesity is multifaceted including but not limited to lower levels of education, poverty, food deserts, and therefore the treatment of obesity should be multifaceted. The task for the dialysis staff then became how to manage dialysis treatment – with unrealistic weight loss expectations and associated side effects
Conclusion:
Patients are looking for the “golden ticket” to assist with weight loss and the GLP-Ras are being hailed as such, however they must be viewed as part of a suite of interventions. The challenge for the dialysis team is how to support the patient while they explore these options and maintain a safe treatment environment.
Abstract
Case Description:
59yo man on HD 3x week with Class 2 obesity (BMI 35.4kg/m2) attended the metabolic rehabilitation clinic and was commenced on OzempicR as part of his weight loss program with the plan to be listed for a renal transplant. A fortnight after commencing OzempicR he began complaining of increasing abdominal pain. Upon investigation he informed the staff he had not moved his bowels in 15days.
Discussion:
Despite the GLP-1Ras being hailed as the golden ticket for people struggling with obesity they are not without their risks and cannot be used in isolation. The underlying cause of obesity is multifaceted including but not limited to lower levels of education, poverty, food deserts, and therefore the treatment of obesity should be multifaceted. The task for the dialysis staff then became how to manage dialysis treatment – with unrealistic weight loss expectations and associated side effects
Conclusion:
Patients are looking for the “golden ticket” to assist with weight loss and the GLP-Ras are being hailed as such, however they must be viewed as part of a suite of interventions. The challenge for the dialysis team is how to support the patient while they explore these options and maintain a safe treatment environment.